1. Home
  2. ZNTL vs JCE Comparison

ZNTL vs JCE Comparison

Compare ZNTL & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$2.41

Market Cap

289.0M

Sector

Health Care

ML Signal

HOLD

JCE

Nuveen Core Equity Alpha Fund of Beneficial Interest

SELL

Current Price

$17.05

Market Cap

288.2M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
ZNTL
JCE
Founded
2014
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
289.0M
288.2M
IPO Year
2020
2007

Fundamental Metrics

Financial Performance
Metric
ZNTL
JCE
Price
$2.41
$17.05
Analyst Decision
Buy
Analyst Count
11
0
Target Price
★ $7.33
N/A
AVG Volume (30 Days)
★ 1.2M
28.0K
Earning Date
11-09-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 18.03
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.21
$13.99
52 Week High
$6.95
$17.45

Technical Indicators

Market Signals
Indicator
ZNTL
JCE
Relative Strength Index (RSI) 32.31 53.67
Support Level $2.09 $16.06
Resistance Level $2.76 $17.11
Average True Range (ATR) 0.16 0.23
MACD 0.02 0.03
Stochastic Oscillator 7.00 59.30

Price Performance

Historical Comparison
ZNTL
JCE

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

Share on Social Networks: